Australian Dry Eye

Click here to edit subtitle

Latest News

view:  full / summary

Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

Posted by australiandryeye on June 9, 2017 at 4:05 AM Comments comments (0)

The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, SYL1001 for the indication of dry eye syndrome. The Company has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program, which is designed to support the submission of a New Drug Application (NDA). The Company has received final, End-of-Phase II meeting minutes from the FDA.


(Log...

Read Full Post »

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial

Posted by australiandryeye on June 9, 2017 at 4:00 AM Comments comments (0)

LEXINGTON, Mass., June 6, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that it has enrolled the first patient into a Phase 2a clinical trial of topical ocular ADX-102 for the treatment of Dry Eye Disease (DED).


 

"Dry Eye Disease is a common ocular inflammatory condition with hig...

Read Full Post »

Lamellar Biomedical Recruits First Patients Into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease

Posted by australiandryeye on June 9, 2017 at 4:00 AM Comments comments (0)


Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on its LAMELLASOME™ technology, announces the recruitment of the first patients in a clinical study assessing LAMELLEYE for the treatment of moderate to severe Dry Eye Disease (DED). Moderate to severe DED is a significant clinical problem for which there are no effective treatments that tackle the underlying cause.



LAME...

Read Full Post »

New Dry Eye Web Store Coming Soon!

Posted by australiandryeye on June 9, 2017 at 12:20 AM Comments comments (0)

AustralianDryEye is currently in the process of developing new webstore to retail products specifically for the needs of dry eye patients.


Stayed tuned for updates.

RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

Posted by australiandryeye on May 14, 2017 at 6:50 AM Comments comments (0)

ROCKVILLE, Md., May 9, 2017 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that its joint venture, ReGenTree LLC, presented the results of its ARISE-1 Phase 2b/3 dry eye clinical trial in a poster session to physicians, scientists, and analysts today at the 2017 ARVO meeting in Baltimore, Maryland.


As previously report...

Read Full Post »

Shire pays $20M for Parions midstage dry eye drug

Posted by australiandryeye on May 13, 2017 at 3:35 AM Comments comments (0)

Shire will pay $20 million upfront, with a potential $535 million biobucks if all goes according to plan, for Parion Sciences’ dry eye candidate P-321 as it looks to boost its ophthalmology pipeline.


The deal sees Shire gain exclusive worldwide rights to develop and commercialize P-321, where it will also lead development. The biopharma added that Parion will have “an opportunity to co-fund” work on the medication.

 

P-321 works as an epith...

Read Full Post »

Novaliq to study novel dry eye treatment

Posted by australiandryeye on May 13, 2017 at 3:35 AM Comments comments (0)

Novaliq announced plans to develop a treatment for ocular neuropathic pain and inflammation in individuals with dry eye disease.


The treatment is being developed in collaboration with the University of Cologne, Germany, the company announced in a press release. 

Dry eye disease (DED) with neuropathic ocular pain is frequently underserved, according to Novaliq. Molecules attempting to target the cannabinoid receptor system are often unstable in water-based formulat...

Read Full Post »

New View of Dry Eye Stresses Mechanisms Over Manifestations

Posted by australiandryeye on May 13, 2017 at 3:35 AM Comments comments (0)

The Tear Film & Ocular Surface Society (TFOS) presented the conclusions and recommendations of the TFOS Dry Eye Workshop II (DEWS II) during a special session of the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting in Baltimore, Maryland, yesterday.

TFOS is a nonprofit, global organization that aims to improve understanding of the composition and regulation of the preocular tear film and its function in maintaining the cornea and conjunctiva, preventin...

Read Full Post »

Sylentis announces new preclinical and clinical data for its SYL1001 molecule during ARVO 2017

Posted by australiandryeye on May 10, 2017 at 1:30 AM Comments comments (0)

SYL1001 is a compound under investigation for the treatment of dry eye disease.


It is a product based on the novel technology RNA interference (RNAi), developed for the treatment of signs and symptoms of this illness.

 

At the Annual Congress of the Association for Research in Vision and Ophthalmology 2017, around 11,000 attendees will meet form the 7-11 of May in Baltimore, USA.

 

Madrid, May, 9th, 2017. In the framework of the Annual Con...

Read Full Post »

Physicists working to cure 'dry eye' disease

Posted by australiandryeye on May 2, 2017 at 11:20 PM Comments comments (0)

The eye is an exquisitely sensitive system with many aspects that remain somewhat of a mystery—both in the laboratory and in the clinic. A U.S.-based team of mathematicians and optometrists is working to change this by gaining a better understanding of the inner workings of tear film distribution over the eye's surface. This, in turn, may lead to better treatments or a cure for the tear film disease known as "dry eye." They describe their work in the journal Physics of Fluids.

Dry...

Read Full Post »

Allergan receives FDA approval for electrical dry-eye device

Posted by australiandryeye on May 2, 2017 at 11:15 PM Comments comments (0)

 


Allergan has gotten Food and Drug Administration approval to market its TrueTear Intranasal Tear Neurostimular, a device the company says increases tear production using electrical stimulation.


Allergan, with headquarters in Dublin and New Jersey, has a unit in Irvine, where it was previously based until it was acquired for about $70 billion by Dublin-based...

Read Full Post »

Could a tear cure dry eyes?

Posted by australiandryeye on May 2, 2017 at 11:15 PM Comments comments (0)

British scientists have patented the design of a biological tear that could be used by millions of people who suffer with eye problems caused by their own tears not working properly.

The most common treatments for dry eyes are lubricants, ointments or artificial tear fluids made from polymers such as methlycellulose (a component of wallpaper paste).

But researchers at Oxford University have discovered the secret of the essential ingredients of real tears, and are working towards d...

Read Full Post »

Not all MGD is dry eye

Posted by australiandryeye on May 2, 2017 at 11:15 PM Comments comments (0)

"The prevalence of asymptomatic MGD is likely higher than we all realize. If we can find MGD and treat the anatomy early, we can save functioning glands and put the patient in a better position to have a healthier tear film long term. Regrettably, a recent survey of practitioners showed that only 30% routinely screen for MGD. Furthermore, work from our own group at Duke is showing that a large percentage of patients coming in for preoperative evaluation have underlying dry eye and MGD.

...

Read Full Post »

Nicox first quarter 2017 business update and cash position

Posted by australiandryeye on May 2, 2017 at 11:05 PM Comments comments (0)


Resubmission to the U.S. FDA, by Nicox, on March 8, 2017 of the NDA for ZERVIATE (cetirizine ophthalmic solution) 0.24%, Nicox’s novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conjunctivitis.


http://www.nicox.com/news-media/nicox-first-quarter-2017-business-update-cash-position/

Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications

Posted by australiandryeye on April 9, 2017 at 9:00 AM Comments comments (0)

Novartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe)

Dry eye is an area with high unmet medical need, impacting over 344 million patients globally[1]


ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye, which in a small phase II study[2] showed the potential to provide instant relief of symptoms and improve signs


Read Full Post »

Protein agent may change approach to treating dry eye, inflammation

Posted by australiandryeye on March 24, 2017 at 8:15 AM Comments comments (2)

Take-home: Recombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.

 

Patients with moderate dry eye disease experienced significant improvement in signs and symptoms following a two-week clinical trial of a recombinant version of the huma...

Read Full Post »

Novel topical peptide for dry eye tackles underlying cause of disease

Posted by australiandryeye on March 24, 2017 at 8:05 AM Comments comments (0)

 

A first-in-class topical synthetic peptide being developed as a treatment for dry eye disease (Lacripep, TearSolutions Inc.) is set to enter into clinical development.

 

The novel proprietary agent, planned to enter a phase I/II trial in March 2017, is a fragment of lacritin, a naturally occurring, eye-selective tear glycoprotein. The agent was discovered in 2001 by Gordon W. Laurie, PhD, professor of cell biology and ophthalmology, University of Virginia, Charl...

Read Full Post »

AXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye Indications

Posted by australiandryeye on March 21, 2017 at 11:50 PM Comments comments (1)

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”;), to perform the company’s upcoming product development (based on AXIM’s IP) and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the worl...

Read Full Post »

Lacritin Clinical Trials Begin mid-April

Posted by australiandryeye on March 18, 2017 at 9:10 PM Comments comments (0)




A University of Virginia Researcher has developed a formula that for the first time treats the causes, not just the symptoms, of dry eyes.


Millions of Americans suffer from dry eyes. To date, over-the counter drops don’t help much.


Gordon Laurie is a professor of cell biology at the University of Virginia and he says the prescription drugs treat on...

Read Full Post »

Rss_feed